ライフサイエンスコーパス: DME

1 DME demonstrated a convincing relationship between BCVA

2 DME is commonly treated with intravitreal injections of

3 DME profiles induced in response to tuberculosis antibio

4 DME with SND correlates with greater CT, more HRS, disru

5 , -0.35 (95% CI, -0.43 to -0.27; P < 0.001); DME, -0.30 (95% CI, -0.48 to -0.09; P = 0.006); and ME f

6 e interval [CI], -0.61 to -0.51; P < 0.001); DME, -0.50 (91 eyes; 95% CI, -0.64 to -0.33; P < 0.001);

7 he new pathway could save pound 1390 per 100 DME visits and between pound 461 and pound 1189 per 100

8 N-CH(2)SiMe(2)NSiMe(3))U(N(SiMe(3))(2))(2)] (DME = 1,2-dimethoxyethane), 1, with 2 equiv of HNEt(3)BP

9 342 IDI injections (203 DME eyes) were included.

10 omplex [TolC identical withMo(OCCH3(CF3)2)3].DME with 2 equiv of functional ynamines or ynamides yiel

11 (6) H(5) ](3) (1), from reaction of NpCl(4) (DME)(2) with four equivalents of K[Me(2) NC(H)C(6) H(5)

12 ursors, ThCl(4)(DME)(2), UCl(4), and NpCl(4)(DME)(2).

13 nd the nonaqueous An(IV) precursors, ThCl(4)(DME)(2), UCl(4), and NpCl(4)(DME)(2).

14 +/- 2.1 (injection frequency: 12.6 +/- 0.7); DME: 11.1 +/- 5.1 (injection frequency: 14.0 +/- 1.0); R

15 VISTA and VIVID randomized 872 DME patients to receive intravitreal aflibercept injecti

16 ERMs and tVC were found in all DME types.

17 Anti-VEGF were 11.6% of all DME treatments in 2009 increasing to 61.9% in 2014, whil

18 7-0.69; PDR HR, 0.45; 95% CI, 0.37-0.54; and DME HR, 0.39; 95% CI, 0.33-0.45), and at the level of ea

19 Patients with type 2 diabetes and DME or PDR have an increased risk of incident CVD, which

20 gaporeans have a higher prevalence of DR and DME compared with Chinese and Malays.

21 associations between the severity of DR and DME with symptoms of anxiety and depression and commonal

22 retina specialists graded images for DR and DME, using National Health Service guidelines as well as

23 al aspects of the production of methanol and DME and outline future research and development directio

24 rative DR (NPDR), proliferative DR (PDR) and DME.

25 ate studies for the decomposition of THF and DME are consistent with monomer-based mechanisms.

26 = 0.012); a similar trend was noted for any DME (P = 0.001) and CSME (P = 0.032).

27 in subgroups with more severe DR and chronic DME at baseline.

28 contributions of these 3 factors to chronic DME.

29 enter of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse).

30 r center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial.

31 Center-involved diabetic macular edema (ci-DME) is a major cause of vision loss.

32 h center-involved diabetic macular edema (CI-DME) with good visual acuity (VA) represent a controvers

33 worsens may be a reasonable strategy for CI-DME.

34 we train a deep learning model to predict ci-DME from fundus photographs, with an ROC-AUC of 0.89 (95

35 laser was safe and effective for treating CI-DME patients with good VA in this case series.

36 e best approach to treating patients with CI-DME and good visual acuity (20/25 or better) is unknown.

37 Among eyes with CI-DME and good visual acuity, there was no significant dif

38 Participants had 1 study eye with CI-DME and visual acuity of 20/25 or better.

39 We report a case series of patients with CI-DME with VA better than 20/32 who were treated with a su

40 ps could receive ranibizumab for concomitant DME.

41 to require additional treatments to control DME.

42 pole leakage index and microaneurysm count, DME was associated with older age (P < 0.01), higher sys

43 ffuse DME showed tVC more often than cystoid DME.

44 central cell of tetraploid plants, DEMETER (DME) is upregulated, which can activate PRC2 family memb

45 ecificity of 31% (95% CI, 23%-40%) to detect DME.

46 Of the 6220 newly diagnosed DME patients, 3010 (48.4%) underwent a follow-up examina

47 Diffuse DME showed tVC more often than cystoid DME.

48 Dimethoxyethane (DME) and N,N,N',N'-tetramethylethylenediamine quantitati

49 fluoroslufonyl)imide (KFSI)-dimethoxyethane (DME) electrolyte forms a uniform SEI on the surface of p

50 Applied to dimethoxyethane (DME) and ethylene carbonate (EC), the present methodolog

51 endo,exo-norbornenyl dialkylesters (dimethyl DME, diethyl DEE, di-n-butyl DBE) were strategically des

52 mine the association of severe stages of DR (DME and PDR) with incident CVD in patients with type 2 d

53 This data supports the IDI use in early DME stages and provide further evidence of better IDI re

54 More eyes with early DME gained 10 or more letters and fewer eyes lost 10 or

55 etinopathy (PDR), or diabetic macular edema (DME) and procedure codes for retinopathy treatments (ant

56 Patients with diabetic macular edema (DME) are at high risk of vascular complications, includi

57 ion of patients with diabetic macular edema (DME) are important for individualizing treatment and opt

58 rse) center-involved diabetic macular edema (DME) at baseline were required to receive ranibizumab fo

59 Diabetic macular edema (DME) can be treated with different alternatives, among t

60 njections (IAIs) for diabetic macular edema (DME) during the phase III VISTA DME trial were maintaine

61 coagulation rates in diabetic macular edema (DME) eyes did not significantly differ from 474/1000 in

62 viously treated (PT) diabetic macular edema (DME) eyes in a real-life setting.

63 ti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improve

64 ickness in eyes with diabetic macular edema (DME) in clinical trials.

65 fective for treating diabetic macular edema (DME) involving the center of the macula (center-involved

66 Diabetic macular edema (DME) is a leading cause of vision loss in diabetics.

67 For example, diabetic macular edema (DME) is a leading cause of vision loss in patients with

68 e implant therapy in diabetic macular edema (DME) is associated with long-term outcome.

69 Diabetic macular edema (DME) is the most common cause of vision loss in diabetic

70 sence of preexisting diabetic macular edema (DME) or postvitrectomy persistent cystoid macular edema

71 degeneration (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO), receiving intravit

72 graphs, we evaluated diabetic macular edema (DME) progression and DR progression.

73 Patients with diabetic macular edema (DME) received three intravitreal injections of 0.5 mg ra

74 Diabetic macular edema (DME) remains a leading cause of vision loss worldwide.

75 SS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizumab.

76 sion areas (NPAs) in diabetic macular edema (DME) using two different Optical Coherence Tomography An

77 Patients with diabetic macular edema (DME) who received sham control or FAc 0.2 or 0.5 mug/day

78 ristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND+) vs DM

79 therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser photocoagulati

80 R), 51 with NPDR and diabetic macular edema (DME), and 18 with proliferative DR (PDR)-and 64 age-matc

81 degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by

82 DR), with or without diabetic macular edema (DME), and temporarily lost to follow-up.

83 acular edema (CSME), diabetic macular edema (DME), or ocular surgery.

84 ity of patients with diabetic macular edema (DME), the most common cause of vision loss in working-ag

85 ity, with or without diabetic macular edema (DME), using en face Doppler OCT.

86 iabetic retinopathy, diabetic macular edema (DME), vision-threatening diabetic retinopathy (VTDR), de

87 mab in patients with diabetic macular edema (DME).

88 or the management of diabetic macular edema (DME).

89 everities of DR, and diabetic macular edema (DME).

90 with center-involved diabetic macular edema (DME).

91 concomitant baseline diabetic macular edema (DME).

92 etic retinopathy and diabetic macular edema (DME).

93 athy (DR), including diabetic macular edema (DME).

94 apy for treatment of diabetic macular edema (DME).

95 for center-involving diabetic macular edema (DME).

96 reatment response in diabetic macular edema (DME).

97 b and bevacizumab in diabetic macular edema (DME).

98 egeneration (AMD) or diabetic macular edema (DME).

99 tion (AMD, n = 400), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400)

100 severe stages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have

101 ening complications (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]), whic

102 tic retinopathy (DR; diabetic macular edema, DME), or noninfectious uveitis (NIU).

103 tery with a MgTFSI2 /MgCl2 /DME electrolyte (DME=1,2-dimethoxyethane, TFSI=bis(trifluoromethanesulfon

104 tive oxidation of methane to dimethyl ether (DME) over Pt/Y(2) O(3) .

105 nversion of synthesis gas to dimethyl ether (DME) was imaged simultaneously and in situ using synchro

106 point to eyes that were not receiving extra DME treatments.

107 of 4 EZ grades in 185 eyes with gradable EZ (DME, 41 eyes; NIU, 144 eyes; P <= 0.050 for all pairwise

108 % (25.9-30.6) for any DR, 7.6% (6.5-9.0) for DME, and 7.7% (6.6-9.0) for VTDR.

109 -step DRSS score improvement at week 100 for DME patients in VISTA and VIVID.

110 We investigated OCT biomarkers for DME treated by intravitreal dexamethasone (DEX) implant.

111 and then under model reaction conditions for DME synthesis (H2:CO:CO2 ratio of 16:8:1, up to 250 degr

112 ne whether reduced TRBF is a risk factor for DME.

113 om 284 patients treated with DEX implant for DME (naive, n = 209; refractory, n = 90).

114 ients with DME receiving >=1 DEX implant for DME-related visual impairment in clinical practice.

115 8 years scheduled to receive DEX implant for DME-related visual impairment.

116 = 0.88) when compared with macular laser for DME; however, there was an increased hazard of post-trea

117 ich contrasts with experiments, at least for DME-based electrolytes.

118 multimodal imaging (spectral-domain OCT for DME, and 7-field Early Treatment Diabetic Retinopathy St

119 hown to be an effective treatment option for DME, although the injections are costly and require freq

120 vailability of various treatment options for DME is essential.

121 nd 25 to the PRP group (plus ranibizumab for DME).

122 Of patients referred for DME, 30.4% were deemed to have treatable DME.

123 ng potential as a new therapeutic target for DME.

124 whether an eye received laser treatment for DME during the study.

125 with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR severity.

126 l of 23 348 patients receiving treatment for DME met inclusion criteria; 13 365 received macular lase

127 macular laser photocoagulation treatment for DME.

128 t, bevacizumab, or ranibizumab treatment for DME.

129 plant is an effective and safe treatment for DME.

130 ermining the initial choice of treatment for DME.

131 he different possible initial treatments for DME (anti-vascular endothelial growth factor [VEGF], foc

132 s (SAEs) in patients receiving anti-VEGF for DME compared with controls treated with macular laser ph

133 ore than 325 mum, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 2

134 atients with specific characteristics (e.g., DME).

135 nts with treatment-naive phakic eyes who had DME, primary therapy with the intravitreal dexamethasone

136 6 participants with PDR and vision-impairing DME at baseline, 21 were assigned to the ranibizumab gro

137 rticipants without baseline vision-impairing DME, 80 and 87 were in the ranibizumab and PRP groups, r

138 yes presenting with PDR and vision-impairing DME, but not for those with PDR without vision-impairing

139 s with and without baseline vision-impairing DME, the incremental cost-effectiveness ratios of ranibi

140 for those with PDR without vision-impairing DME.

141 e) DME and without baseline vision-impairing DME.

142 of patients in nAMD (0% after 1 year); 0% in DME (0% after 1 year); and 31.3% in RVO (0% after 1 year

143 cy: 7.4 +/- 0.4) respectively 6.1 +/- 4.7 in DME (n = 9; injection frequency: 8.4 +/- 1.1) and 9.7 +/

144 otable differences were found in nAMD and in DME, with VA significantly higher in some RCTs and lower

145 ilure in EC electrolyte and capacity fade in DME electrolyte.

146 l in identifying various imaging findings in DME.

147 ular endothelial growth factor inhibitors in DME could be associated with an increase in cardiovascul

148 compared with sham with and without laser in DME.

149 Anti-VEGF therapy has become a mainstay in DME treatment, with PPP, although relatively low, also i

150 y, in the presence of ( S)-Ir-II (5 mol%) in DME solvent at 60-70 degrees C, alpha-methyl allyl aceta

151 0.27) and RVO (r = -0.72) trials, but not in DME trial data.

152 C6 H3 ) with H2 SiI2 in a 3:1 molar ratio in DME afforded a mixture of the separated ion pair [(cAACM

153 causes a significantly greater reduction in DME than that seen with suppression of VEGF alone.

154 sponsored (Genentech or Novartis) studies in DME completed as of December 31, 2013.

155 the poor structural response to treatment in DME.

156 priority for the management of DR, including DME, but few were associated with Cochrane reviews.

157 th 1 year of medical coverage before initial DME treatment.

158 ng the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or wo

159 id not have vision-impairing center-involved DME at baseline.

160 VEGF treatments in eyes with center-involved DME causing vision impairment.

161 27 eyes of 26 patients with center-involved DME that underwent vitrectomy with peeling of the intern

162 tive effectiveness trial for center-involved DME was conducted in 650 participants receiving afliberc

163 b for vision impairment from center-involved DME, patients not driving at initiation of treatment are

164 d to receive ranibizumab for center-involved DME.

165 d to receive ranibizumab for center-involved DME.

166 ial ranibizumab therapy for center-involving DME likely have better long-term vision improvements tha

167 r treatment-naive eyes with center-involving DME previously enrolled in a prospective study were revi

168 SND-) with treatment-naive, center-involving DME were evaluated.

169 ine laser control eyes with center-involving DME were included.

170 The [K(DME)2][Ce horizontal lineN(3,5-(CF3)2C6H3)(TriNOx)] comp

171 Furthermore, the superconcentrated KFSI-DME electrolyte shows excellent electrochemical stabilit

172 or more letters compared with eyes with late DME (47.4% vs. 33.9% [P = 0.001] and 8.2% vs. 13.5% [P =

173 ecco's modification of Eagle's basal medium (DME) produce no transformed foci when grown to confluenc

174 argeable Mg/S battery with a MgTFSI2 /MgCl2 /DME electrolyte (DME=1,2-dimethoxyethane, TFSI=bis(trifl

175 action pathway of sulfur cathode in MgTFSI2 -DME electrolyte, as well as the associated kinetics are

176 sly reported U(IV)/U(IV) nitride complex [Na(DME)(3)][((Me(3)Si)(2)N)(2)U(mu-N)(mu-kappa(2):CN-CH(2)S

177 Naive DME eyes received lower number of IDI injections and sho

178 Although eyes with naive DME gained more vision than refractory eyes (P < 0.001),

179 ory treatment for macular edema due to nAMD, DME and RVO.

180 No DME-like condition was noticed even after 7 months.

181 Forty eyes of 40 patients with PDR and no DME were enrolled in this study.

182 sponders, from subjects with diabetes but no DME, and from age-matched volunteers without diabetes.

183 egeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

184 iteracy was high-65% of AMD patients, 73% of DME patients, and 63% of patients with RVO.

185 yzed to determine the presence or absence of DME, central subfield thickness (CST), and subretinal fl

186 These data may improve characterization of DME in eyes with SND.

187 Classification of DME comprised sponge-like diffuse retinal thickening, cy

188 es irrespective of the OCT classification of DME type or presence of ERM.

189 Patients with a diagnosis of DME were identified using International Classification o

190 anti-VEGF treatment, with a control group of DME patients receiving regular anti-VEGF treatment witho

191 and III were positive tested irrespective of DME type.

192 ical coherence tomography for persistence of DME at longitudinal follow-up visits.

193 d the independent association of presence of DME with macular leakage index and macular microaneurysm

194 th regard to DR severity and the presence of DME.

195 th regard to DR severity and the presence of DME.

196 Prevalence of DME based on monocular fundus photographs or OCT.

197 ents with type 2 diabetes, the prevalence of DME was 4.6% and PDR, 7.4%.

198 me measures were incidence or progression of DME or DR and change in visual acuity.

199 EGF doses required to maintain regression of DME.

200 associated with the presence and severity of DME.

201 ial growth factor agents in the treatment of DME as well as the difference in response between patien

202 ti-VEGF pharmacotherapy for the treatment of DME in routine clinical practice.

203 th intravitreal aflibercept for treatment of DME provides simliar visual benefit at 24 weeks' follow-

204 gest patient-level data sets on treatment of DME with ranibizumab.

205 eillance study, DEX implant for treatment of DME-related visual impairment in the Indian population d

206 as a therapeutic target for the treatment of DME.

207 RISE studies of ranibizumab for treatment of DME.

208 significant predictors for the worsening of DME and visual acuity when the treatment interval was ex

209 bizumab or aflibercept) due to either AMD or DME comorbidity, showed a significant reduction of RGC a

210 = Li, K, Rb, Cs; solv = TMEDA, THF, Et2O, or DME), was isolated and fully characterized.

211 c non-nucleophilic solvents (such as MeCN or DME), leading to a mixture of the benzofurofuranone deri

212 etween TZD use and visual acuity outcomes or DME progression, and no consistent evidence of increased

213 JT were associated with any DR, NPDR, PDR or DME.

214 ns were less likely to develop NPDR, PDR, or DME and modest evidence that these patients are less lik

215 tions had a diagnosis code for NPDR, PDR, or DME or a procedural code for intravitreal injections, pa

216 Persistent DME was present in 50.8 and 31.6% of the 190 aflibercept

217 53.2 and 72.9%, respectively, had persistent DME at month 3, and 41.5 and 65.6%, respectively, had pe

218 41.5 and 65.6%, respectively, had persistent DME at month 6.

219 months 3-6) used in patients with persistent DME at month 6 was 180, 219 and 354 for aflibercept, ran

220 correlations were identified in both pooled DME (r = -0.45) and pooled RVO (r = -0.35) trial data at

221 medium correlation was identified in pooled DME trial data (r = -0.42).

222 e ranibizumab 0.5 mg PRN based on predefined DME re-treatment criteria.

223 the role of quantitative UWFA in predicting DME development and characterizing patient prognosis.

224 ckness (CRT) were evaluated for naive and PT DME eyes over 24 months.

225 jections and showed better VA levels than PT DME eyes for 24 months in a real-world setting.

226 tions was significantly lower in naive vs PT DME eyes (1.40 +/- 0.9 vs 1.82 +/- 0.9, p < 0.001).

227 tion was significantly higher in naive vs PT DME eyes (76.1 vs 47.7), (p < 0.001).

228 ores were consistently better in naive vs PT DME eyes at all studied timepoints, with no significant

229 n array of monodisperse polymers (PLA(x)-ran-DME(1-x))n bearing variable grafting densities (x = 1.0,

230 elected by literature search: nAMD: 13 RCTs, DME: 9, RVO: 5), the OCEAN patients' mean age was signif

231 Eyes with persistent or recurrent DME were managed with pro re nata anti-VEGF agents.

232 maintain visual acuity in residual/recurrent DME after FAc.

233 IAIs in the presence of clinically relevant DME.

234 Thirty-seven DME eyes were included.

235 rative DR, proliferative DR, and significant DME.

236 a 12-week induction period, there was still DME resolution in an increasing number of patients throu

237 The DME productivity (mumol g(cat) (-1) h(-1) ) was comparab

238 ercept Injection in Vision Impairment Due to DME)-in a multicenter setting.

239 Panretinal analyses were not linked to DME as strongly.

240 o underlying pathways and their relevance to DME prognosis.

241 ed when choosing an anti-VEGF agent to treat DME.

242 for DME, 30.4% were deemed to have treatable DME.

243 ee of accuracy in the detection of treatable DME.

244 e pathway for people with previously treated DME or PDR.

245 extend algorithm of ranibizumab in the TREX-DME trial resulted in significantly fewer injections and

246 Under DME reaction conditions at 1 bar, the coexistence of Cu(

247 Sixty patients completing VISTA DME elected to enter the ENDURANCE extension study.

248 ed visual acuity gains achieved during VISTA DME were maintained and stable with individualized dosin

249 cular edema (DME) during the phase III VISTA DME trial were maintained with individualized, as-needed

250 ision gains achieved during the 3-year VISTA DME trial were maintained through M12 of the ENDURANCE e

251 subfoveal neuroretinal detachment (SND+) vs DME without SND (SND-).

252 ts, the only carbon-containing products were DME and CO(2) .

253 ted for 3,614 patients with nAMD, 1,211 with DME, 204 with BRVO and 121 with CRVO.

254 TZD use was not associated with DME incidence in either the analysis of any use (adjuste

255 nce in neovascular AMD and RVO compared with DME, which was represented rarely in the population stud

256 All patients newly diagnosed with DME from 2013 through 2016 were observed for 90 days aft

257 e medical records of patients diagnosed with DME who had undergone intravitreal injection.

258 Diabetic eyes with DME exhibited lower TRBF than healthy eyes (P </= .001).

259 Eyes with DME had larger AVC, VT, FAZ-A, and FAZ-CI and lower VD t

260 an early surgical intervention in eyes with DME irrespective of the presence of traction formation i

261 e TRBF was consistently low in the eyes with DME regardless of DR severity.

262 s to improve long-term outcomes in eyes with DME seems warranted to determine if VA can be better mai

263 Eyes with DME showed a decrease in leakage index from 3.5+/-2.7% a

264 leakage index values revealed that eyes with DME showed a significantly higher microaneurysm count (P

265 with DME that were treated and the eyes with DME that were not treated was not identified.

266 A difference in TRBF between the eyes with DME that were treated and the eyes with DME that were no

267 ctive review of medical records of eyes with DME treated with 0.7 mg intravitreal dexamethasone impla

268 F was 28.0 (8.5) microL/min in the eyes with DME, 48.8 (13.4) microL/min in the eyes with DR but with

269 In eyes with DME, monthly intravitreal ranibizumab injections resulte

270 For eyes with DME, parafoveal VD in the superficial layer at baseline

271 Among eyes with DME, those with submacular fluid, no HRF, and a continuo

272 hat improve anatomical outcomes in eyes with DME.

273 did not significantly change among eyes with DME.

274 (23%) eyes, and moderate to severe NPDR with DME in 3 (23%) eyes.

275 apse in anti-VEGF treatment in patients with DME did not appear to result in significant anatomic or

276 of the phase 3 VISTA study in patients with DME provides evidence that regular IAI dosing not only c

277 implant over 1 year in Indian patients with DME receiving >=1 DEX implant for DME-related visual imp

278 cans obtained from a cohort of patients with DME throughout the 1st year of treatment.

279 unintended treatment lapse in patients with DME undergoing anti-VEGF therapy.

280 wever, uncertainty remains for patients with DME who are at high risk for vascular disease and were n

281 tios (IRRs) were estimated for patients with DME, PDR, and vision-threatening DR, compared with perso

282 eability by aqueous fluid from patients with DME.

283 and VEGF-A with faricimab for patients with DME.

284 the eyes of diabetic mice and patients with DME.

285 5 total score over 52 weeks in patients with DME; these were even more pronounced for near than for d

286 Anti-VEGF therapy was indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, an

287 Persons with DME or PDR were more likely to have incident CVD (IRR, 1

288 Patients whose eyes were phakic with DME (<3 months) were included if the central subfield th

289 in a multicenter institutional practice with DME exhibiting an unintended minimum 3-month lapse in an

290 Twenty-four eyes of 24 subjects with DME were included in this institutional review board-app

291 In subjects with DME, sustained intraocular delivery of FAc slows develop

292 ntly different between eyes with and without DME in univariate assessment.

293 ith moderate nonproliferative DR but without DME exhibited a wide range of TRBF from 31.1 to 75.0 mic

294 ) microL/min in the eyes with DR but without DME, 40.1 (7.7) microL/min in the diabetic eyes without

295 In eyes without DME, PRP use declined from 1017/1000 in 2012 to 707/1000

296 he posterior pole compared with eyes without DME.

297 or PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe NPDR with DM

298 In this study of eyes with PDR without DME, both monthly and quarterly aflibercept injection gr

299 % CI, 1.49-3.67) compared with those without DME or PDR.

300 mpairing (Snellen equivalent 20/32 or worse) DME and without baseline vision-impairing DME.